Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Poor Performance Status Clinical Trial

Official title:

Exploration of the Clinical Application of Almonertinib in the First-line Treatment of Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer With Poor Performance Status

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05826483
• Other study ID #: CROC202201
• Status: Recruiting
• Phase: Phase 1
• Start date: January 1, 2022
• Est. completion date: December 30, 2024

Study information

• Verified date: April 2023
• Source: Guangzhou Institute of Respiratory Disease
• Contact: Zhou Chengzhi, MD
• Phone: 13560351186
• Email: doctorzcz[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore, the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.

Description:

Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.In recent years, systemic treatments with good efficacy and low toxicity, such as gene-targeted therapy, anti-angiogenic therapy and immunotherapy, have largely replaced single chemotherapy, and have great potential to benefit from existing treatments for poor PS scores of advanced lung cancer patients can adopt more aggressive treatment strategies.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore,the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 30, 2024
• Est. primary completion date: December 28, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

2. Male or female who is over 18 years old.

3. Malignant tumorsr proved by pathology.

4. NSCLC patients with EGFR mutation (19 deletion/21 L858R point mutation) or primary T790M mutation in pre-enrollment genetic testing.

5. PS score of 2-4; this score is caused by complications caused by the tumor and cannot be improved by any non-anti-tumor means.

6. Patients with brain metastases may be enrolled at the discretion of the investigator.

7. Appropriate organ system function.

Exclusion Criteria:

1. Patients who have previously used any antineoplastic drugs?

2. Small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);

3. Genetic testing results in patients with rare EGFR genotypes (G719X, E709X, Del18 on exon 18, Ins19 on exon 19, Ins20, S768I on exon 20, and L861Q on exon 21).

4. Patients with other mutations (ALK, Ros-1, C-MET).

5. Imperfection of upper gastrointestinal physiology, or absorption disorder syndrome, or inability to tolerate oral drugs, or active peptic ulcer;

6. Participated in other clinical trials within 4 weeks before the start of the study;

7. patients with hypertension who cannot control well through single antihypertensive medication (systolic blood pressure > 140mmhg, diastolic blood pressure > 90mmhg), myocardial ischemia or myocardial infarction, arrhythmia (including QT interval > 440 ms) or cardiac insufficiency;

8. Allergic to any ingredient in the drug;

9. Patients with abnormal coagulation function, receiving thrombolysis or anticoagulation therapy, bleeding tendency or have clear gastrointestinal bleeding concerns;

10. Hyperactive/venous thrombosis events, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism occurred in 6 months before the start of the study;

11. Wound or fracture has not been healed for a long time;

12. urinary protein was greater than ++ and 24-hour urinary protein quantification #1.0 g.

13. Severe or uncontrolled infections;

14. Substance abuse or mental disorder;

15. Objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe impairment of pulmonary function;

16. Immunodeficiency, including being HIV-positive, or having other acquired, congenital immunodeficiency diseases, or having a history of organ transplantation;

17. Other malignant tumors within 5 years, except cured basal cell carcinoma of the skin and orthotopic carcinoma of the cervix;

18. Who have received VEGFR inhibitors, such as sorafenib and sunitinib, etc.;

19. pregnant or lactating women;

20. the researchers considered it unsuitable for inclusion?

Related Conditions & MeSH terms

• Lung Neoplasms
• Neoplasms
• Poor Performance Status

Intervention

Drug:
• Almonertinib
Almonertinib Mesilate Tablets

Locations

Country	Name	City	State
China	Zhou Chengzhi	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Institute of Respiratory Disease

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety: Dose-limiting toxicities	Any level 3 or greater toxicity	from the screening period to 28 days after treatment completion
Primary	ORR	Objective Response Rate	24 months
Primary	Time of PS score change from 2~4 to 1	Time of performance status score change from 2~4 to 1	6 months
Secondary	PFS	Median progression-free survival	24 months
Secondary	OS	Median overall survival	from baseline until death due to any cause, up to a maximum of approximately 4years
Secondary	DCR	Disease control rate	24 months